ODYSSEY THERAPEUTICS
Odyssey Therapeutics is a computational immunology company that develops novel therapeutics for patients with autoimmune diseases. Using modern machine learning techniques, Odyssey is transforming the landscape of autoimmune treatments. Odyssey Therapeutics was founded in 2018 and is based in San Francisco, California.
ODYSSEY THERAPEUTICS
Industry:
Biotechnology Health Care Life Science Machine Learning Therapeutics
Founded:
2018-06-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.odysseytherapeutics.com
Total Employee:
1+
Status:
Closed
Email Addresses:
[email protected]
Total Funding:
101.63 M USD
Founder
Investors List
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series A - Odyssey Therapeutics
Official Site Inspections
http://www.odysseytherapeutics.com
- Host name: ec2-54-161-222-85.compute-1.amazonaws.com
- IP address: 54.161.222.85
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Odyssey Therapeutics"
Odyssey Therapeutics - Crunchbase Company Profile
Odyssey Therapeutics is a computational immunology company that develops novel therapeutics for patients with autoimmune diseases. Using modern …See details»
Odyssey Therapeutics - Crunchbase Company Profile
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery …See details»
About Odyssey Therapeutics
We have established a replicable and scalable model for drug discovery and development and are advancing a diversified portfolio of programs with the intention of efficiently delivering safe and effective medicines to patients with …See details»
Odyssey Therapeutics
Oct 28, 2024 Odyssey Therapeutics and Terray Therapeutics Enter Strategic Collaboration to Jointly Discover and Develop First-in-Class Transcription Factor Therapies. October 27, 2024. …See details»
Odyssey Therapeutics, Inc.
Odyssey Therapeutics's series C brings the biotech’s total raised to $487 million since launching in 2021. ... The statistics for drugs in the Pipeline is the current organization and its …See details»
Odyssey Therapeutics - Overview, News & Similar companies
Dec 31, 2023 View Odyssey Therapeutics (www.odysseytx.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well …See details»
Odyssey Therapeutics - LinkedIn
Odyssey Therapeutics is a computational immunology company creating innovative therapies for patients with autoimmune diseases. Despite a significant fraction of the aging U.S. population ...See details»
Odyssey Therapeutics Company Profile 2024: …
Odyssey Therapeutics General Information Description. Operator of a biotechnology company intended to develop immunomodulators and oncology drugs. The company aims to advance the drug discovery space with its …See details»
Odyssey Therapeutics - VentureRadar
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next generation immunomodulators and oncology medicines. Comprised of an expert team of drug …See details»
Odyssey Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Odyssey Therapeutics, Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
Odyssey Therapeutics Company Profile: Overview and Full News …
Odyssey Therapeutics, Inc. is a biotechnology company pioneering next-generation precision immunomodulators for inflammatory diseases . The SAB will be chaired by Stephen Blacklow, …See details»
Glick's Odyssey raises $168M to gear up for clinic - Fierce Biotech
Oct 13, 2022 The Odyssey Therapeutics story is progressing quickly. Ten months after disclosing a $218 million series A, the Gary Glick-helmed biotech is back with another mega …See details»
Odyssey Therapeutics Expands Management Team with Key …
Boston, Mass., November 9, 2022 -- Odyssey Therapeutics, Inc., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today …See details»
Odyssey Bags $168M to Accelerate Push to the Clinic
Oct 13, 2022 Odyssey Founder and CEO Gary D. Glick/Courtesy Odyssey Therapeutics. Odyssey Therapeutics raised $168 million in a Series B financing round, which will be used to …See details»
Odyssey raises epic $101M to push programs off to clinical sea
Dec 5, 2023 Odyssey Therapeutics has raised a $101 million Series C to help get its next-gen precision immunomodulators and oncology medicines into the clinic.See details»
Odyssey Therapeutics launches with $218 million
Dec 7, 2021 Odyssey Therapeutics isn’t Gary Glick’s first biotech start-up. Or his second. It’s his fifth. The serial entrepreneur has earned a reputation for launching one company after another …See details»
Odyssey Therapeutics Announces Oversubscribed $168 Million …
Boston, Mass., October 13, 2022 — Odyssey Therapeutics, Inc., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today …See details»
Suprachoroidal drug delivery: a versatile therapeutic platform
Dec 6, 2024 In catheter-based systems, a catheter is generally inserted manually through a scleral incision and advanced posteriorly. The iTrack™ 250A microcatheter, developed by …See details»
News - Odyssey Therapeutics
Oct 28, 2024 Odyssey Therapeutics to Present New Data on its Clinical-Stage RIPK2 Scaffolding Inhibitor, OD-07656, at the American College of Gastroenterology (ACG) Annual …See details»
Odyssey Therapeutics Announces Strategic Collaboration to …
BOSTON, April 4, 2024 — Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision medicines, announced today it has entered into a strategic research …See details»